IR Information

  • English translation not available.

Biopharmaceutical Pioneer in Japan

JCR has been proactively engaged in research and development (R&D) of biopharmaceuticals based on recombinant DNA technologies from early on as a Japanese pharmaceutical company.  In 1993, the recombinant human growth hormone product, Growject®, was launched.  Meanwhile development of a therapeutic drug for renal anemia, recombinant human erythropoietin, began in around 2000 and was approved for manufacturing and marketing in February 2010 as the first domestic biosimilar in Japan. In May 2010, the product was launched as Epoietin Alfa BS Injection JCR. Learn more

Top page